Angelo Matturro studied Pharmaceutical Chemistry and Technologies at the University of Salerno (Italy). After experience in Genetic spa gained in 5y with focus on development equivalent drugs working with different dosage forms in ophthalmic and inhalation therapeutic area, Angelo joined Chiesi in 2017 as CMC Analytical Scientist in R&D with focus on development drugs in inhalation field.

In 2023 he successful completed the European Course of Pharmaceutical Medicine (ECPM) at University of Basel, broadening their knowledge of cutting-edge developments in the fields of Medtech, Pharma and Biotech. His expertise is in inhalation field with focus on pMDI drug development. He coordinates and supports all analytical activities mainly for clinical late phase up to the market and Life Cycle Management of pharmaceutical products. Currently his role is R&D Strategic Technical Leader accountable for define the CMC strategic plan for NCEs and late-stage projects. Recently join as speaker the FDA-CRCG Workshop on Navigating the Transition to Low Global Warming Potential Propellants